Rapidly progressive glomerulonephritis (RPGN) is characterized by the rapid deterioration of the renal function associated with crescent formation on renal biopsies. This report describes a case of RPGN caused by anti-glomerular basement membrane (GBM) glomerulonephritis in an elderly man with severe thrombocytopenia and a platelet count of 1.4×10 4 /μL. Thrombotic microangiopathy (TMA) and heparin-induced thrombocytopenia (HIT) were implicated in the severe decrease in platelets. This report also discusses the pathological background and clinical management of TMA and HIT among patients with anti-GBM glomerulonephritis.
Introduction
Rapidly progressive glomerulonephritis (RPGN) is characterized by the rapid deterioration of the renal function and the observation of crescent formation on renal biopsy specimens (1) . Crescentic glomerular injury is recognized to occur in various types of glomerular disease, including antiglomerular basement membrane (GBM) glomerulonephritis, immune complex-mediated glomerulonephritis and antineutrophil cytoplasmic antibody ( ANCA ) -associated glomerulonephritis (1, 2) . The initial pathogenic steps may be distinct; however, they eventually merge to a substantial degree forming a final common process of injury that results in glomerular inflammation, necrosis, leakage of fibrinfibrinogen into the urinary space and crescent formation (3) . This report describes a case of RPGN caused by anti-GBM glomerulonephritis in an elderly man with thrombocytopenia. Thrombotic microangiopathy (TMA) and heparininduced thrombocytopenia (HIT) were implicated in the severe decrease in platelets.
Case Report
A 68-year-old man was admitted in September 2010 due to rapid deterioration of his renal function and general fatigue. Although he had no past medical history of renal disease, his serum creatinine (sCr) level was 1.02 mg/dL at the end of August 2010 and further increased to 2.65 mg/dL at the beginning of September 2010. Fifteen years prior to admission, the patient was found to have mild hypertension, for which he had received no medical care. He had smoked for more than forty years and denied the use of any drugs.
A physical examination performed at the time of admission revealed the patient to be alert and afebrile with edema in the lower extremities. The patient's blood pressure was 169/103 mm Hg, his pulse was 89 beats/min and his respiratory rate was 12 breaths/min. Although the patient's oxygen saturation was 97% while he breathed ambient air, a chest X-ray film demonstrated an accumulation of fluid in the left thorax. There were no rashes or lymphadenopathy, and no petechiae were found. The patient's heart sounds were normal. Renal sonography revealed that the size of both kidneys and the renal cortex echogenicity were slightly HBs antibodies and antibodies to the hepatitis C virus were all negative; however, anti-GBM antibodies were detected at a level of 30 enzyme-linked immunosorbent assay unit (EU). A urinalysis revealed a urine protein level of 2+ and a red blood cell count of 10-12/HPF. The proteinuria selectivity index was 0.42. The creatinine clearance was 27.7 mL/ min. The levels of urinary excretion of β2-microglobulin and N-acetyl-beta-D-glucosaminidase were 139,678 μg/L and 27.0 U/g·Cr, respectively. A renal biopsy contained two cores of renal parenchyma with ten glomeruli, three of which were globally sclerotic. Although hyalinizations were seen in several glomeruli, there was no evidence of vasculitis in the blood vessels. The rest of the glomeruli exhibited cellular crescents and fibrinoid necrosis with Bowman's capsules that were almost completely destroyed. Marked interstitial infiltration of inflammatory cells was also noticed. An immunohistochemical analysis failed to demonstrate the presence of IgG along the glomerular capillary walls (Fig. 1) .
The patient was ultimately diagnosed with RPGN caused by anti-GBM glomerulonephritis based on the serological and pathological findings. The oliguria persisted and the renal function progressively deteriorated despite the administration of corticosteroids combined with furosemide, and the initiation of hemodialysis (HD) was required (Fig. 2) . A gradual decrease in the platelet count to 14.2×10 4 /μL was noted 15 days after the initiation of HD. The platelet count continued to decrease to a nadir of 1.4×10 4 /μL over the following two weeks in association with the progression of anemia despite the presumptive discontinuation of the agents, including furosemide and omeprazole, both of which had been administered at least six days until the 29th hospital day. The patient was found to have an elevated level of LDH at 401 IU/L, a decreased level of serum haptoglobin on negative direct and indirect Coombs' tests and occasional schistocytes on peripheral blood smears, suggesting the latent presence of TMA (4) . The activity of a disintegrin-like and metalloproteinase with thrombospondin type I motif 13 (ADAMTS 13) was retained at 70%. On the other hand, a serological analysis revealed the presence of anti-platelet factor 4 (PF4)/heparin complex antibodies. Therefore, daily heparin flushes of the dialysis catheter were discontinued at the beginning of October 2010, and the anticoagulant therapy for HD was switched from nafamostat mesilate to argatroban at a dose of 5 mg/hr on the 36th hospital day. At that time, the initial session of plasma exchange (PEX) combined with argatroban, which replaced three liters of plasma with the same amount of fresh frozen plasma, was also administered. A hollow fiber polyethylene membrane filter with an average pore size of 0.3 μm and an effective surface area of 0.8 m 2 (OP-08; Asahi medical Co., Tokyo, Japan) was used as the plasma separator. Test results for both anti-GBM and anti-PF4/heparin complex antibodies became negative in association with elevations in the levels of both Hb and hematocrit (Hct) immediately after the first PEX session. However, the patient's platelet count remained around 4 to 6×10 4 /μL despite the continuous administration of 30 mg/day of argatroban combined with 100 mg/day of aspirin. Moreover, the patient continued to exhibit decreases in the level of haptoglobin, subsequently requiring the administration of another session of PEX. The hemolytic and thrombocytopenic responses lagged behind for an additional twelve weeks after the platelet count and haptoglobin level normalized (Fig. 2) . The patient's deteriorated renal function persisted, and a periodic HD program was continued.
Discussion
The poor prognosis of patients with glomerulonephritis with extensive crescent formation has been documented for several decades, and various regimens of corticosteroids, immunosuppressants, anti-coagulants and anti-inflammatory agents have been administered to ameliorate glomerular damage with varied degrees of success (1) . Moreover, the clinical significance of PEX in the treatment of various types of crescentic glomerulonephritis, especially anti-GBM glomerulonephritis, has been evaluated, and improvements in the renal function occurring after the initiation of PEX have been demonstrated in several studies (5-7). However, this regimen has so far never been properly assessed due to the rarity and acuteness of RPGN; therefore, the monotherapeutic significance of PEX in patients with RPGN remains to be elucidated. Indeed, it was difficult to precisely evaluate the clinical impact of PEX in the current case since the therapy was administered as an adjunct treatment to corticosteroids. Nevertheless, the immediate disappearance of anti-GBM and anti-PF4/heparin complex antibodies with a partial but prompt recovery in the levels of Hb and Hct and the platelet count just after the initial session of PEX suggest that the procedure was advantageous, at least in part, in controlling the accompanying disease activities implicated in the development of severe thrombocytopenia.
TMA is a pathological condition characterized by thrombosis of small vessels, intravascular breakdown of red blood cells, elevations in the levels of serum LDH and consumption of platelets. Hemolytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) have received attention as two typical phenotypes of TMA (4, (8) (9) (10) ; however, TMA is also associated with other clinical conditions, such as malignant hypertension, malignancies, posttransplantation and various types of glomerular injuries (10) . Not surprisingly, an association between TMA and anti-GBM glomerulonephritis has been demonstrated as well (11) (12) (13) (14) (15) . There may be an etiological link between an ADAMTS 13-dependent mechanism and the development of TMA in patients with anti-GBM glomerulonephritis (13, 14) ; however, this was not the case in the current patient since no decreases in the ADAMTS 13 activity were confirmed. Previous reports of TMA occurring in association with varied diseases imply that vascular lesions might be associated with glomerular injuries or other as yet undetermined immune-mediated vascular injuries; however, they are not a specific disease entity. The gradual but transient decreases in LDH observed during each session of PEX might be related to immunomodulative effects on the as-sumptive immune-based pathogenesis of TMA (1); however, the overall impact of PEX in the current case should be evaluated carefully since the clinical benefits of PEX have been primarily confirmed in TMA patients with decreased ADAMTS 13 activity (10, 13) . Indeed, in the present case, schistocytes were still detectable on peripheral blood smears and gradual increases in the serum LDH level resumed, even after the second session of PEX was administered, suggesting that the TMA was persistent and refractory to PEX, although we failed to confirm any significant decreases in the serum level of haptoglobin. Otherwise, the condition may have been associated with the degree of fibrinoid necrosis within the kidneys, which may also have determined the grade of glomerular damage (4, 8) . Interestingly, we confirmed severe destruction of GBMs on the renal biopsy, which can result in negative immunostaining for IgG along the glomerular capillary walls (3), as demonstrated in the current patient. Meanwhile, the presence of vasculopathies associated with TMA, such as occluded arterioles with fibrin plugs or schistocytes, was not confirmed in the renal biopsy specimen of the current patient. This is not surprising, however, since clinical phenotypes and pathological findings may not necessarily be confirmed simultaneously (16, 17) . Finally, the fact that the titer of anti-GBM antibodies increased, even after the initiation of steroid treatment, led us to consider that there might be further tissue damage associated with the development of TMA, especially in light of the renal biopsy findings. At present, we do not know whether the duration of thrombocytopenia after the second session of PEX in the current case was reasonable, although a similar period before the clinical remission of thrombocytopenia and hemolysis due to TMA may not be exceptional (14) .
Although there is no information available regarding the lower limit for platelet counts among patients with TMA, the severe decrease in the platelet count observed in the current case led us to consider that an alternative pathological mechanism was also associated with the development of thrombocytopenia in the present patient. Various agents have been implicated in the development of thrombocytopenia (18) ; however, we failed to confirm any improvements in several clinical parameters, including the platelet count, the haptoglobin level and the serum LDH level, despite the discontinuation of the suspicious agents. Instead, further serological evaluations revealed the presence of anti-PF4/heparin complex antibodies, suggesting the involvement of HIT in the excessive consumption of platelets (19, 20) . The time period between the onset of thrombocytopenia and the administration of heparin varies according to a patient's history of exposure; however, delays of five to ten days are typical in patients with HIT with no previous exposure or remote histories of exposure (21) . Patients who require HD and/or PEX could be at risk for HIT since anticoagulation therapy with heparin is the standard treatment in these procedures. In the current case, heparin was not used as an anticoagulant for HD; however, daily heparin flushes of dialysis catheters should play a pivotal role in the development of HIT. Indeed, there are several reports of cases of HIT induced by heparin flushes, although the precise frequency with which such conditions lead to HIT remains to be elucidated (22, 23) .
The goal of treating HIT is to reduce the risk of thrombosis by reducing platelet activation and thrombin generation. All sources of heparin should be discontinued, and initial treatment requires several types of anticoagulant agents such as argatroban (21) . Therapeutic PEX may also have potential benefits for the treatment of HIT, although there is limited information available regarding this issue (24, 25) . Treatment with PEX and argatroban seemed to be partially successful in recovering the platelet count in the current case; however, the persistence of thrombocytopenia despite continuous administration of argatroban combined with aspirin suggested that HIT may be less responsible for the development of thrombocytopenia than TMA in the present patient. An association between anti-GBM glomerulonephritis and HIT may not be exceptional (26) ; however, the lack of data regarding such conditions suggests that the combination of these diseases is exceedingly rare. Nevertheless, the widespread use of heparin as an anticoagulant agent and/or heparin flushes for dialysis catheters in patients with RPGN who are dialyzed or treated with PEX implies that physicians are likely to encounter this problem. Conducting further studies and accumulating additional clinical cases are required to better determine the optimal management of RPGN in patients with TMA and/or HIT.
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